Market Overview

Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat

Related GILD
Analysts On Gilead: We Think They're Mobilizing For A Deal
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... (GuruFocus)

Gilead Sciences (NASDAQ: GILD) is down less than one percent in after hours trading after the company announced its fourth quarter results.

The company reported a Q4 EPS of $0.55 versus the Street estimate of $0.50.

Earnings per share were up 10 percent from the year-ago period.

Revenue arrived at $3.12 billion versus the Street estimate of $2.85 billion. Sales were up 20 percent year-over-year.

Gilead also announced that product sales increased 21 percent to $3.04 billion for the fourth quarter of 2013. This is notably higher than the $2.51 billion that Gilead reported during the fourth quarter of 2012.

Full year product sales rose to $10.8 billion (up from $9.4 billion in 2012). Sales of Stribild, Complera, Eviplera and Sovaldi were attributed to the company's continued success.

Antiviral product sales also increased, rising 22 percent to $2.64 billion during the fourth quarter. For all of 2013, antiviral product sales reached $9.34 billion -- up from $8.14 billion during the previous year.

At market close yesterday (Monday, February 3, 2014), Gilead was up more than four percent year-to-date.

The stock has performed well over the past year, rising more than 99 percent since February 4, 2013.

Disclosure: At the time of this writing, Louis Bedigian had no position in the equities mentioned in this report.

Posted-In: Complera Eviplera Gilead Sciences Sovaldi StribildEarnings News


Related Articles (GILD)

View Comments and Join the Discussion!